Mepron Related Published Studies
Well-designed clinical trials related to Mepron (Atovaquone)
Prolonged Protection Provided by a Single Dose of Atovaquone-Proguanil for the Chemoprophylaxis of Plasmodium falciparum Malaria in a Human Challenge Model. [2011.11.03]
Efficacy of atovaquone and azithromycin or imidocarb dipropionate in cats with acute cytauxzoonosis. [2011.01]
Malaria treatment with atovaquone-proguanil in malaria-immune adults: implications for malaria intervention trials and for pre-exposure prophylaxis of malaria. [2008.04]
Atovaquone plus cholestyramine in patients coinfected with Babesia microti and Borrelia burgdorferi refractory to other treatment. [2006.01]
Atovaquone-proguanil for treating uncomplicated malaria. [2005.10.19]
A randomized comparison of artesunate-atovaquone-proguanil versus quinine in treatment for uncomplicated falciparum malaria during pregnancy. [2005.09.01]
Short report: no evidence of cardiotoxicity of atovaquone-proguanil alone or in combination with artesunate. [2005.08]
Malaria prophylaxis for aircrew: safety of atovaquone/proguanil in healthy volunteers under aircraft cabin pressure conditions. [2005.07]
Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection. [2005.01.01]
Efficacy of combined atovaquone and azithromycin for therapy of chronic Babesia gibsoni (Asian genotype) infections in dogs. [2004.07]
Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: results of an international, randomized, open-label study. [2004.06.15]
CV8, a new combination of dihydroartemisinin, piperaquine, trimethoprim and primaquine, compared with atovaquone-proguanil against falciparum malaria in Vietnam. [2004.02]
Atovaquone and proguanil versus amodiaquine for the treatment of Plasmodium falciparum malaria in African infants and young children. [2003.12.01]
Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil. [2002.12.15]
Efficacy of atovaquone/proguanil for malaria prophylaxis in children and its effect on the immunogenicity of live oral typhoid and cholera vaccines. [2002.11.15]
Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity. [2002.11.01]
Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia. [2002.10.01]
Atovaquone plus chloroguanide versus mefloquine for malaria prophylaxis: a focus on neuropsychiatric adverse events. [2002.09]
Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039. [2002.05.01]
Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. [2001.10.01]
Causal prophylactic efficacy of atovaquone-proguanil (Malarone) in a human challenge model. [2001.07]
The effect of atovaquone on etoposide pharmacokinetics in children with acute lymphoblastic leukemia. [2001.06]
Atovaquone and proguani hydrochloride compared with chloroquine or pyrimethamine/sulfodaxine for treatment of acute Plasmodium falciparum malaria in Peru. [2001.04]
Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team. [2000.12.02]
Atovaquone and azithromycin for the treatment of babesiosis. [2000.11.16]
Atovaquone plus proguanil versus halofantrine for the treatment of imported acute uncomplicated Plasmodium falciparum malaria in non-immune adults: a randomized comparative trial. [2000.11]
A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. [1999.10]
Absence of an interaction between artesunate and atovaquone--proguanil. [1999.08]
Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. [1999.08]
Lack of a pharmacokinetic interaction between atovaquone and proguanil. [1999.06]
Pharmacokinetics of azithromycin administered alone and with atovaquone in human immunodeficiency virus-infected children. The ACTG 254 Team. [1999.06]
Atovaquone-proguanil compared with chloroquine and chloroquine-sulfadoxine-pyrimethamine for treatment of acute Plasmodium falciparum malaria in the Philippines. [1999.06]
Combination atovaquone and proguanil hydrochloride vs. halofantrine for treatment of acute Plasmodium falciparum malaria in children. [1999.05]
Prophylactic activity of atovaquone against Plasmodium falciparum in humans. [1999.05]
Atovaquone and proguanil versus pyrimethamine/sulfadoxine for the treatment of acute falciparum malaria in Zambia. [1999.05]
Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand. [1999.04]
A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. [1999.04]
Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. [1998.12.24]
Relative bioavailability of atovaquone suspension when administered with an enteral nutrition supplement. [1998.10]
Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. [1998.09]
Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. [1998.03.07]
Atovaquone and proguanil for the treatment of malaria in Brazil. [1997.06]
Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. [1997.05]
Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone. [1996.11]
Atovaquone has no effect on the pharmacokinetics of phenytoin in healthy male volunteers. [1996.08]
Atovaquone and proguanil for Plasmodium falciparum malaria. [1996.06.01]
Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. [1996.01]
Adverse events associated with trimethoprim-sulfamethoxazole and atovaquone during the treatment of AIDS-related Pneumocystis carinii pneumonia. [1995.05]
The role of atovaquone tablets in treating Pneumocystis carinii pneumonia. [1995.03.01]
Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Atovaquone Study Group. [1994.08.01]
Clinical experience with atovaquone: a new drug for treating Pneumocystis carinii pneumonia. [1994.07]
Examination of some factors responsible for a food-induced increase in absorption of atovaquone. [1994.01]
Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. [1993.05.27]
Well-designed clinical trials possibly related to Mepron (Atovaquone)
Azithromycin for treating uncomplicated malaria. [2011.02.16]
Use of peroxisome proliferator-activated receptor gamma agonists as adjunctive treatment for Plasmodium falciparum malaria: a randomized, double-blind, placebo-controlled trial. [2009.09.15]
Drugs for treating uncomplicated malaria in pregnant women. [2008.10.08]
Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial. [2008.09.16]
Randomized, double-blind, placebo-controlled study of Malarone for malaria prophylaxis in non-immune Colombian soldiers. [2006.09]
Folic acid treatment of Zambian children with moderate to severe malaria anemia. [2006.06]
A randomized open label clinical trial to compare the efficacy and safety of intravenous quinine followed by oral malarone vs. intravenous quinine followed by oral quinine in the treatment of severe malaria. [2005.02]
Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. [2003.11.08]
Other research related to Mepron (Atovaquone)
Re-emergence of Babesia conradae and effective treatment of infected dogs with
atovaquone and azithromycin. [2012]
Cyclodextrin/poly(anhydride) nanoparticles as drug carriers for the oral delivery of atovaquone. [2011.12]
Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis. [2011.05.21]
SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood-brain barriers. [2011.02]
A potential interaction between warfarin and atovaquone. [2011.01]
Efficacy of atovaquone and azithromycin or imidocarb dipropionate in cats with
acute cytauxzoonosis. [2011]
Acute disseminated fatal toxoplasmosis after haploidentical stem cell transplantation despite atovaquone prophylaxis in a young man. [2010.11]
Does atovaquone prolong the disease-free interval of toxoplasmic retinochoroiditis? [2010.08]
Assessment of adherence to atovaquone-proguanil prophylaxis in travelers. [2010.07]
Plasmodium chabaudi chabaudi malaria parasites can develop stable resistance to atovaquone with a mutation in the cytochrome b gene. [2010.05.21]
Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir. [2010.05.15]
Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection. [2010.02.01]
[Effects of combined addition of atovaquone and lithium on the in vitro cell growth of the pathogenic yeast Candida albicans] [2010.02]
Oral atovaquone for the treatment of severe Pneumocystis jirovecii pneumonia in a patient with glucose-6-phosphate dehydrogenase deficiency. [2010]
Possible emergence of drug-resistant variants of Babesia gibsoni in clinical cases treated with atovaquone and azithromycin. [2009.05]
The role of apolipoprotein E in uptake of atovaquone into the brain in murine acute and reactivated toxoplasmosis. [2009.05]
Breakthrough cerebral toxoplasmosis in a patient receiving atovaquone prophylaxis after a hematopoietic stem cell transplantation. [2008.12]
Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanil. [2008.11.20]
Toxoplasmosis in wallabies (Macropus rufogriseus and Macropus eugenii): blindness, treatment with atovaquone, and isolation of Toxoplasma gondii. [2008.08]
Bullous erythema multiforme after treatment with Malarone, a combination antimalarial composed of atovaquone and proguanil hydrochloride. [2008.07]
Mutation underlying resistance of Plasmodium berghei to atovaquone in the quinone binding domain 2 (Qo(2)) of the cytochrome b gene. [2008.06]
Atovaquone-proguanil resistance in imported falciparum malaria in a young child. [2008.06]
Failure of atovaquone/proguanil to prevent Plasmodium ovale malaria in traveler returning from Cameroon. [2008.05]
[Tolerance and efficacy of atovaquone-proguanil for the treatment of paediatric imported Plasmodium falciparum malaria in France: clinical practice in a university hospital in Paris] [2008.03]
Plasmodium falciparum malaria and atovaquone-proguanil treatment failure. [2008.02]
In vitro atovaquone/proguanil susceptibility and characterization of the cytochrome b gene of Plasmodium falciparum from different endemic regions of Thailand. [2008.01.28]
Treatment of refractory Babesia microti infection with atovaquone-proguanil in an HIV-infected patient: case report. [2007.12.15]
A systematic review and meta-analysis of the effectiveness and safety of atovaquone proguanil (Malarone) for chemoprophylaxis against malaria. [2007.11]
Relapsing vivax malaria after 6 months of daily atovaquone/proguanil in Afghanistan: the case for expanded use of primaquine as a causal prophylactic. [2007.11]
Babesia gibsoni: detection during experimental infections and after combined atovaquone and azithromycin therapy. [2007.10]
A systematic review and meta-analysis of the effectiveness and safety of atovaquone proguanil (Malarone) for chemoprophylaxis against malaria. [2007.09.10]
Parallel evolution of adaptive mutations in Plasmodium falciparum mitochondrial DNA during atovaquone-proguanil treatment. [2007.08]
Efficacy of atovaquone-proguanil for treatment of acute multidrug-resistant Plasmodium falciparum malaria in Thailand. [2007.04]
Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. [2007.03]
Cerebral malaria in spite of peripheral parasite clearance in a patient treated with atovaquone/proguanil. [2007.03]
Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II). [2007.02]
Atovaquone and azithromycin treatment for babesiosis in an infant. [2007.02]
A randomised, double-blind, placebo-controlled trial of atovaquone-proguanil vs. sulphadoxine-pyrimethamine in the treatment of malarial anaemia in Zambian children. [2006.11]
Tertian malaria (Plasmodium vivax and Plasmodium ovale) in two travelers despite atovaquone-proguanil prophylaxis. [2006.11]
Efficacy and safety of atovaquone-proguanil compared with mefloquine in the treatment of nonimmune patients with uncomplicated P. falciparum malaria in Japan. [2006.10]
|
